Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.49 |
| ▸ | IGF1R | P08069 | 1/20 | 0.49 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.47 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.47 |
| ▸ | JAK3 | P52333 | 14/20 | 0.47 |
| ▸ | PTK2 | Q05397 | 12/20 | 0.47 |
| ▸ | JAK2 | O60674 | 11/20 | 0.47 |
| ▸ | LCK | P06239 | 2/20 | 0.47 |
| ▸ | BTK | Q06187 | 1/20 | 0.47 |
| ▸ | WNT3A | P56704 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10157513 | 0.85 | EML4 (0.53) | NAMPTIGF1RDDB1CRBNJAK3 | |
| SCHEMBL328440 | 0.82 | EML4 (0.54) | NAMPTIGF1RJAK3PTK2JAK2 | |
| SCHEMBL10156169 | 0.81 | EML4 (0.46) | PTK2 | |
| SCHEMBL10206189 | 0.76 | PTK2 (0.54) | NAMPTIGF1RJAK3PTK2JAK2 | |
| SCHEMBL17630908 | 0.76 | IGF1R (0.54) | NAMPTIGF1RDDB1CRBNJAK3 | |
| SCHEMBL21965379 | 0.74 | NAMPT (0.66) | NAMPTIGF1RDDB1CRBNJAK3 | |
| SCHEMBL28041286 | 0.74 | PTK2 (0.56) | IGF1RJAK3PTK2JAK2 | |
| SCHEMBL21946817 | 0.74 | JAK3 (0.59) | NAMPTIGF1RDDB1CRBNJAK3 | |
| SCHEMBL21946815 | 0.74 | JAK3 (0.62) | NAMPTIGF1RDDB1CRBNJAK3 | |
| SCHEMBL6917548 | 0.73 | NAMPT (0.67) | NAMPTIGF1RDDB1CRBNJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120040968-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | WATERS TECHNOLOGIES CORPORATION (US) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040968-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | EML4, ALK, ERBB4 | NAMPT 1441/4885IGF1R 1399/4885DDB1 422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.